Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Q-Linea, Audiocast with teleconference, Q2'24

By Inderes7/11/2024, 11:00 AM
Q-Linea

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Stuart Gander
00:01 - 15:36

Hello and good afternoon, everyone. This is Stuart Gander here, CEO of Q-linea AB. I'm joined by my CFO Christophe Samuelson for this Q2 report. So thank you for taking the time to join us. Um, we'll do this similar to previous webcasts; I will make some opening comments to give you a general sense of where we are in the business. Um, some of the highlights from the last quarter include, Uh, and then I'll turn it over to Christophe, Who will walk us through the financials for the quarter. So with that, just a quick flash of our regular disclaimer here. So you've read that with respect to any forward-looking statements. Um, a few of the key messages I wanted to make sure that you hear during our discussion today include, Number one, following the FDA approval at the end of April, we're now in full commercial push mode in the US. Um, I'll speak to it more in detail, but obviously, this is a very large market, with a significant opportunity for rapid growth. So we're being very thoughtful in terms of how we approach and segment it. So we utilize our relatively small commercial team on the ground where we have the most opportunity for early-stage traction. So I'll talk a little bit about that second piece related to our commercial expansion on the geographic side. We've had a presence now in Western Europe for some time. And with the expansion into the US, our focus is now shifting to a global and steady expansion of the ASTar opportunity around the world. Um, obviously, there are a great number of geographies and potential partners. So, we're being thoughtful in terms of how we deploy resources and which markets we enter at what time, so that we don't get too far over our skis, but at the same time open up new opportunities for ASTar to reach patients. Thirdly, we've talked about this before, but the cost-saving program that was initiated at the beginning of this year has been completed. Christophe will speak more to the details, but all of those changes have been done as planned and on time. And in fact, on the cost side, we're slightly above the cost reduction projection that we anticipated or, to be precise, slightly more savings than we anticipated. So we will see those coming through the back end of this year and then finally, again, as communicated previously, we're very pleased that we've had an extended financing arrangement with Nexttobe, our largest shareholder. And that will carry us through into the back part of this year. So those are some of the key messages and with that I'll get into the next level of detail here. As for areas of focus for me since joining and stepping into the role roughly four months ago, Number one, that commercial acceleration is paramount. So we have now shipped our first instruments to the US with dedicated US software and specifications. And with the FDA approval, we now have a US-approved menu. The instruments that are now being installed can remain on-site once customers sign the contract. Previously, customers had the opportunity to use the ASTar platform under early access programs and for clinical work. But now, these are commercial instruments being sent to the US for evaluations. A key point here is our ongoing reception of support from CMS regarding NTAP reimbursement funding. We have not yet received final approval from CMS, but they have recommended reimbursement coverage at $97.50 per patient. So, this would be applicable for any Medicare patients undergoing a rapid AST test on the ASTar platform. This will help laboratories and hospitals offset the costs of rapid AST tests. We expect this will not only accelerate the adoption of rapid AST but will also promote the consideration of ASTar by hospitals and laboratories. Commercial traction in our other core markets has also continued. We have shipped an additional unit to Italy. We announced another tender that we are participating in in Belgium. Several other markets are showing progress in terms of customers evaluating and contracting our ASTar platform. We hope to share more updates on these developments soon. As I mentioned previously, we are thoughtfully considering our geographic expansion and customer engagement on both the scientific and commercial fronts. I also noted in last quarter's report our presentations at ASM, which were very well received. We have interim results from our health economics and outcomes research study in Italy. We shared highlights of these results at the ASM conference in the US, which continued to generate strong interest from customers, and it's encouraging to see the broader industry invest in publications on the benefits of rapid AST. This has become a prominent topic with an increasing body of evidence supporting the practical and clinical advantages of rapid AST for hospitals. My second area of focus, following customer acceleration, has been on innovation and product development. The recent FDA approval marks a culmination of significant effort by our team to secure access to the US market. Our work doesn't stop there. We have submitted the second version of our menu, which will provide additional drug-bug combinations to our US customers, further enhancing our offering. Throughout this period of restructuring, which posed significant demands on the organization, we have successfully met all internal development milestones. This underscores the commitment and capabilities of our development team. We continue to expand the capabilities of ASTar with next-generation software and additional menu options. The third focus area for me has been organizational development. Having completed the restructuring process, we are now settling into the new organizational structure moving forward. We are making targeted investments, including in the US market, where we have added team members to enhance our commercial launch, significantly boosting our presence in that market. We are also focusing on strengthening the end-to-end customer care and service support experience. We anticipate deploying a number of our instruments globally in the near future. And this will place more demands on the service team. So this is one of the key areas of, uh, focus for the team in the months ahead. And then finally, on the financial side, um, overall tracking ahead of the budget that was set. Uh, we see those costs coming down slightly faster than anticipated, which is good news. Krista will speak to that more in detail. Um, you know, my focus and that of the team, really, uh, remains on driving the top line growth. Uh, keeping in mind that in many of the markets, we will expect to see reagent rental models, which means when instruments go out, it does take a little bit of time for the revenues to come in as usage of those. uh, you know, grows over time and, and, and customers buy and use kits for their patients. So with that, um, maybe I'll just jump into some further comments. Um, for those that are new to rapid AST, um, you know, it's worth reiterating our core proposition, which is, in our view, a market-leading one. The platform promises a less than six hour turnaround time for critical blood infections. Um, uh, diagnosis, uh, which both in terms of clinical impact has a clear benefit in reducing the impact of sepsis and saving lives. It also saves time and money, and critically lab time. And in managing the patient workflow. Um, the actual workflow on the instrument is second to none. It's less than two minutes of hands-on time. Very simple interface and critically is a continuous access and random access platform with very minimal training needed for a user, making it very easy to plug into any microbiology lab around the world. Um, and then finally, with respect to that menu, very comprehensive menu. Um, and continues to demonstrate very strong performance in the field with respect to consistency, reproducibility of test results. So here's a quick view of our US-cleared ASTar panel. Uh, we received that clearance on April 26th, so we're very proud of that. Um, this panel will continue to be strengthened. As I mentioned earlier, with a version two, um, we will leverage the clinical data that's been gathered over the next few months for that resubmission. Um, and we will expect to see that, uh, in the quarters ahead. So with respect to the US market, um, you know, as I mentioned, there's, uh, it's a very special and big market, uh, geographically large and relatively complex in terms of the makeup of different types of hospitals, labs, configurations, etc.. So, uh, the first order of business for us is to be very thoughtful and structured. Uh, the team has done a great job segmenting the roughly 1600 or so labs that we think are relevant for the platform, and really focusing on the top 50 to around 100 of those centers. These are the labs, both that have the volumes, um, that, that make it very interesting to start there. But also crucially, are ones that have proven themselves to be early adopters of technologies. They often have key opinion leaders and thought leaders in the field. The types of decision makers that can move quickly with their lab to bring new and beneficial technologies to their patients. We are actively engaging with several dozen of these and are now setting up evaluations over the coming months. So, we'll expect to see the contracting periods for those comments after the evaluations. The main thing here for us is to really demonstrate the performance of ASTar by getting the instrument into the hands of lab techs and lab managers who use it day to day. And we see consistently very strong feedback once the instrument is in the lab, that folks see the benefits and the usability advantages of the ASTar approach. We believe this will lead to a very strong reception, based on the evaluations that we're now setting up. Attention will eventually shift from initiating evaluations to the conversion in contracting over the coming months. In support of that customer engagement, I had the privilege of joining the team in Atlanta in June for the ASM conference, which is the largest US-based microbiology conference. It sort of mirrors in some ways the earlier estimated conference. We were obviously able to leverage some of those similar scientific findings for our poster presentations. And it gives us an opportunity to interact with more than 5000 clinicians and scientists in the field across the US. It was interesting to note that, as with ECCMID, rapid AST remains a focus area for research and scientific endeavor in the field. We're also not the only players discussing this space. As I mentioned, there are a number of studies and poster presentations coming out that really further support the clinical benefits of rapid AST. Um, so speaking to that, it's worth highlighting again, the interim results from our health economics and outcomes research in Italy. We've discussed this previously, but the numbers are worth highlighting again, as we see up to 34 hours of improvement in time to result when using ASTar versus the current standard of care in the sepsis environment, where every hour counts and every hour leads to increased mortality. This has tremendous benefits for the outcome of the patient. We've noted in the interim results that nearly half, just under half of patients had an adjustment in therapy. That means that these patients are either receiving, in many cases, an escalation in therapy that would suggest that their clinical outcomes may have been worse had they not received a different, inappropriate therapy. Crucially, improved stewardship and retaining the ability to use our most impactful drugs for patients truly when it matters. Rather than addressing the antimicrobial resistance challenge. So, this is just some of the data that's coming out into the market and encouraging the shift towards rapid AST. So just to round off a little bit here, um, you know, we continue to focus very much in the immediate phase here on the commercializatioon of the ASTar platform. In Europe, in the US, and now increasingly globally, our development pipeline is focused on further strengthening the proposition of the ASTar. Uh, with menu expansion. We've mentioned, for example, Gram-positive, which is another roughly 50% of the patients with bloodstream infections. We would expect to expand that menu in the future. Additionally, down the road, there are further applications pertaining to other test types and modalities moving forward. So with that, I'll turn over the comments to Kristen to highlight the financial developments for the quarter.

Unknown
15:36 - 15:37

Thank you, Stuart.

Christopher Samuelson
15:37 - 21:56

Thank you, Stuart. I'll start off by discussing some financial highlights for the quarter. As Stuart already mentioned, we have completed the cost savings program that was initiated earlier this year. And it has been a really good savings program. And we can see the full effect from the $50 million savings in Q3 and onwards. We are happy about that one. As Stuart mentioned, we have also been offered an additional loan facility, and the total loan facility from our main owner, Nexttobe, now amounts to 101.5 million. The unutilized part as of June 30 is 60 million Swedish kronor. Looking at the cash and available loan facilities as of the 30th of June, the total amount is 80.9 million. The operating result for the second quarter is negative fifty-seven million. If we exclude the restructuring costs of $8.4 million, which primarily pertains to personnel costs representing 100%, we would then report a minus $19 million result for the month in the second quarter. This is in line with the results from the first quarter of this year. Switching to the equity side, I just want to highlight that the parent company equity amounts to 163 million as of June 30th, and the equity includes 70 million from the valuation of the technology. And that only goes for the parent company equity. It doesn't affect the group equity. Switching to our consolidated statement of profit and loss for the second quarter. The top line was, uh, fairly low. As you can see, it's 1.6 million compared to last year's 1.9 million. And that explains why we have a low top line, even though we have delivered a couple of instruments, we don't see the income coming. It will come later. And in short, if you aren't familiar with the reagent rental model, we get paid when we sell the consumables. So, the consumable price will include everything from both the consumables and the instrument. The operating result, as I've stated before, was negative 65.4.

57 million minus the restructuring cost, thanks to this cost savings program. Earnings per share were -0.56 for the quarter, significantly lower than last year, which is explained by the rights issue we had last year, increasing the number of shares substantially. As you can see, this is the consolidated statement of financial position. As stated before, we have 20.9 million in cash and cash equivalents. Starting off the year with 81.9 million. We have utilized 41.5 million of the loan facility from the main owner. Looking at the average monthly burn rate for the second quarter, it amounted to 16.7 million, which was slightly lower than for the first half of the year when it amounted to 17.1 million. As stated before, as of June 30th, we had 80.9 million in available funds. Inventory is moving in the right direction. Our revenue is lower than last year, at 40.4 million, and is also lower than at the end of Q1, which is positive. And we still have a large number of instruments, which is positive in the phase we are now in. I talked earlier about the parent company equity, and now I'll switch to the group equity, which amounted to 68.1 million at the end of the second quarter. We have experienced an average monthly decrease of 18.9 million. On the equity side, I've already covered the parent company equity, so I'll skip that. Switching to the last page and future financing, I will briefly summarize the financial side here. As previously stated, we have 80.9 million in available funds, and a total loan facility of 101.5 million from our main owner, approved by the AGM on the 30th of June. Our average monthly operating result for the second quarter was -19 million, excluding the restructuring cost of 8.4 million. As stated before by Stuart and myself, the cost savings programs will have their full effect starting with Q3 and Q4, and we feel confident that this will occur. And as some of you might have seen, we have reported that we do not have concerns regarding going concern on that topic. But we are still summarizing where we are. We are still in an early commercialization phase. We launched after we secured funding, and our sales funnels are growing and maturing, but we have to be proactive in pursuing alternative financing options. These include, as stated before, strategic partnerships, capitalization of existing assets with Q-linea, and negotiations with new and existing owners, investors, and financiers. It is the Board of Directors' assessment that the group will successfully be able to finance company operations going forward. Stuart,

Stuart Gander
21:59 - 22:08

Great, thank you, Christopher. That concludes our board comments here. Are there any questions from the audience? Also in written form.

Operator
22:11 - 22:43

If you wish to ask a question, please press the Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please press the Pound Key six on your telephone keypad. The next question comes from Johann Aeneas from Redeye. Please go ahead.

John
22:48 - 23:26

Thanks for taking our questions. I have a few if I may. Okay, I'm hearing an echo. Yes, I'm hearing double. Um, what about the prospect of a US commercial partner? Obviously, the US launch is very important during the early stage, as the approval and reimbursement seem to come along later this year. Um, any engagements with potential US commercial partners?

Stuart Gander
23:28 - 24:33

Yeah, thank you. John. Uh, good to hear from you. Uh, so on the partnership side, we continue to explore partners around the world. Um, we've chosen a partner-led model for most geographies outside Europe, including the US. Um, on the US side, there are certainly benefits to that. We continue to engage with different potential partners in discussions at this point. Um, you know, no decisions or nothing to specifically communicate on that one. Um, I would comment that, in these early days, right now, it's beneficial for us to be able to engage directly, so that we get immediate feedback from the market on ASTar and its benefits, and how we might further develop that. Um, and also, you know, the opportunity to shape the market growth directly with our message and our version of rapid AST. Um, that isn't to say that going forward, there wouldn't be a clear benefit from engaging a commercial partner. But at this stage, we're very satisfied with the internal team that's opening the market.

John
24:34 - 25:02

Yes, and to follow up on that, you're pointing out some 50 to 100 prioritized institutions; then could you provide us with a feel for the process, even if it's early days? I mean, even if there is substantial interest from some of these institutions early on. Presumably there is a process of engagement and decision-making and implementation.

Stuart Gander
25:03 - 28:55

Yeah. Great question. Um, and this is the key thing that defines the shape of our funnel and the timing and so on, to get into patient tests in the end. Um, so typically we would see a process in 3 or 4 stages where the first stage is fairly open and vague. It's just around that initial assessment and two-way engagement. Uh, basically the dating process, if you will, of trying to figure out if we're the right solution for them and they are the right customer for us. Uh, and that process is about understanding the current lab situation. Um, you know, their volumes, the types of patients they have, and also what stage of their own financial economic cycle they're in. Are they in a capital buying cycle right now, or is this something they'll be more interested in a reagent rental, so that, you know, can be as short as a couple of months or it can take, you know, half a year or more, depending on how high the level of interest is here. I would say that right now the types of customers we're engaging with That period is relatively short because again, we've pre-screened for those that are likely to be of most interest right now. And, you know, we have the luxury of picking and choosing a little bit here in the beginning, whom we engage with. And folks are coming up to us at the conferences and so on. Um, you know, moving on from that phase, you have one of evaluation, and typically, customers will want to see the instrument working for a couple of months in their lab. It can take a little bit of time to set up that evaluation. Labs have different information systems, requirements, and space requirements. It can take 2 to 3 months to set up and run that evaluation in the lab. Then there's a period that can vary from a few weeks to a couple of months, where they evaluate the results of the in-lab evaluation and present them to their peers and decision-makers. So again, three to six months at the longer end for an evaluation. From there, you move into commercial contracting and negotiation. Some of this legwork has already been done well in advance. The team will have given the customer some indicative quotes. But now, post-evaluation and with further review of their volumes and more discussions, you can have more specific conversations on the pricing model and volume discounts, among other things. This phase can be as short as 1 to 2 months if the site is already set up and keen to get going, or it can take quite some time for multi-site, large reference lab groups with potentially dozens of labs that will want to take some time here and think it through. However, some customers can move fairly quickly through that. And then the final stage is just the setup in their final installation. This involves connecting over to their standard of care and ensuring fully aligned integration. Final checks are performed internally before they flip the switch and go with the new standard of care for their clinical protocol. Usually, this final setup is fairly quick. Short as a month, it can take a little bit of time if they need to get some final approvals and whatnot operationally. So that whole end-to-end cycle, you would typically expect it to last 15 to 18 months. The initial phase, as I mentioned, is very hard to determine. But once you're into that evaluation phase, we would expect to see 12 to 15 month cycle times until full deployment and large patient volumes.

John
28:56 - 29:19

Great, that's useful. In terms of providing an external field for investors and the likes, can we expect you to present a number of evaluations or any other feedback from this process going forward?

Stuart Gander
29:20 - 30:46

Yes, I think it's a fair question. We've actively discussed it. What form of guidance to give? #As Kristen pointed out, financially, it's very difficult, even if we place an instrument, to predict exactly what the pull through rate will be, as it's up up to the customer to determine. We are still at early stages and do not have an installed base generating very predictable routine revenue. But you're right, the evaluation should be forward indicators of contracting. I think it's a good point. It's something we're considering - should we make that information more available? Obviously conscious about not mentioning specific customers and so on. An evaluation is not necessarily indicative of a commercial opportunity. We have evaluations with customers that have, you know, 500 or 1000 patients a year. We have evaluations with customers that are well in excess of 5,000 for whole systems, representing tens of thousands of customers. These are some of the realities as we try to be thoughtful in providing more visibility on the forward development of the business without misleading in any way. Um, so just to understand our thinking there.

John
30:47 - 31:21

That sounds reasonable. It should be a good starting point, without necessarily providing a narrow indication for sales prospects at that stage. You seem to have made progress in the markets of Italy and Belgium, for example.

Stuart Gander
31:23 - 32:49

Yes, we see the processes moving along as expected. Tender-driven processes are always longer. In my experience, for example, the US tends not to have tenders, and they can operate a bit more dynamically. We are seeing both an increase in the number of tenders coming in now and also observing those moving forward. In general, I think I mentioned previously in my comments, the development in Europe is slower and longer, just by the nature of those markets, compared to the US, which has already been primed for rapid AST. Previously, there has been a competitor in that market with a previous generation for some time. Um, and just the dynamics of the US market and, for example, our funding mechanisms specifically encourage adopting novel technologies quickly. Whereas Europe is a fragmented market, it takes different approaches, and the funding and reimbursement mechanisms for labs can be quite complex. So we continue to work through those questions, but we see progress across our core markets and would expect to see that growth progressing further. Slower, slower than the US, but slow and steady.

John
32:50 - 33:29

Yes. And finally, from our side, on the financial side, you have completed the restructuring process, which seems like we can expect you to expand the commercial US team somewhat and the support side on that side. And what about the run rate in terms of opex and cash burn? Once the restructuring is in place, particularly during Q3 and towards the end of the year, is it possible to provide a sense of what to expect?

Stuart Gander
33:30 - 33:32

Christopher, do you want to take that one?

Christopher Samuelson
33:32 - 34:06

It's a good question. Thank you, Joanne. Uh, and that is the annual savings. So, you can always divide that 50 million by 12. And I think you will be pretty close to where we will be in Q3 and Q4. On the OpEx and the operating result side. So that's the guidance we can give.

John
34:07 - 34:18

And there is no reason to expect any. Difference in the sort of cash flow and result impact of the 50 million.

Christopher Samuelson
34:19 - 34:46

I would say the risk is low. It's fairly low. There's always one in the ramp-up phase we are in. We have the working capital to handle and manage. I think we are on top of that. That means we have to actually purchase and increase the purchases on the commercial side. So that will tie up some capital, but I think we are on top of that one. So no, I think the risk is fairly low as I see it.

John
34:47 - 34:51

Yeah. Okay. Thank you. That's all from us.

Stuart Gander
34:53 - 34:54

Thank you. Ewan.

Operator
34:57 - 35:04

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad.

Unknown
35:11 - 35:11

Any further?

Operator
35:12 - 35:20

There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Stuart Gander
35:26 - 35:41

All right. I don't see any written questions. So if there's nothing else, I think we can conclude for this quarter. So, thank you all for joining and look forward to speaking with you again in roughly two months.

Unknown
35:42 - 35:45

Thankung you. Great.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…